Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Daniel Botelho Costa, M.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
1995 - 2000
MD (FMRP-USP, Brazil)
2001 - 2004
Intern and Resident in Internal Medicine (Yale, New Haven, CT)
2004 - 2007
Fellow in Hematology/Oncology (Harvard-BIDMC, Boston, MA)
2004 - 2008
PhD (UNICAMP, Brazil)
2007 - 2009
MMSc - Clinical Investigator Training Program (Harvard Medical School-MIT)
2007 - 2010
Staff Physician and Instructor in Medicine (Harvard-BIDMC)
2010 - 2015
Staff Physician and Assistant Professor of Medicine (Harvard-BIDMC)
2015
Staff Physician and Associate Professor of Medicine (Harvard-BIDMC)

Overview
Lung cancer is the leading cause of death from cancer in the United States. Better understanding of oncogenes and tumor suppressor genes involved in lung cancer hold the promise of improving clinical care of afflicted patients.

Prior work from our group has focused on transcription factors involved in lung cancer and mechanisms of sensitivity/resistance of oncogene kinases (such as EGFR, ALK, ROS1, MET, BRAF, RET, ERBB2, NTRK, KRAS among others) to tyrosine kinase inhibitors in non-small-cell lung cancer.

Our group is also part of the clinical research effort at Dana-Farber/Harvard Cancer Center (DFHCC), with a focus in lung cancer, tumor genomic biomarkers and immune checkpoint inhibitors. We are supported by both federal and non-federal grants, and were part of the previously funded NIH/NCI SPORE in Lung Cancer at DFHCC.

One of the main focuses of the DFHCC Lung Cancer Program, in conjunction with the Cancer Clinical Trials Office (CCTO) at Beth Israel Deaconess Medical Center (BIDMC), is to conduct clinical trials that will establish the future evidence-based strategies to manage local, locally advanced and advanced lung cancers.

(co-investigators at BIDMC: Susumu Kobayashi, MD, PhD, Daniel G. Tenen, MD, Sidharta P. Gangadharan, MD; Alexander Bankier, MD, PhD; Adnan Majid, MD; Paul A. VanderLaan, MD, PhD and Deepa Rangachari, MD)

(co-investigators at DFCI: Pasi A. Janne, MD, PhD; Geoffrey Oxnard, MD; Michael Eck, MD, PhD; Matthew Meyerson, MD, PhD; David A. Barbie, MD; Mark Awad, MD, PhD; and Bruce E. Johnson, MD)

(co-investigators at MGH: Lecia V. Sequist, MD, MPH; Zofia Piotrowska, MD; Justin Gainor, MD and Alice Shaw, MD, PhD)

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA218707 (COSTA, DANIEL BOTELHO) Feb 1, 2018 - Jan 31, 2023
    NIH/NCI
    Unmet needs for specific subsets of EGFR mutated lung cancer
    Role: Principal Investigator
  2. R37CA218707 (COSTA, DANIEL BOTELHO) Feb 1, 2018 - Jan 31, 2023
    NIH/NCI
    Unmet needs for specific subsets of EGFR mutated lung cancer
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Rangachari D, Costa DB. From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer. J Clin Oncol. 2019 Jun 02; JCO1901207. PMID: 31154918.
    Citations:    
  2. Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019 Jul; 133:96-102. PMID: 31200835.
    Citations:    
  3. Varkaris A, Sehgal K, Rangachari D, Costa DB. Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer. J Thorac Oncol. 2019 Feb; 14(2):e34-e36. PMID: 30683297.
    Citations:    Fields:    
  4. Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, Shapiro MA, Muzikansky A, Murthy S, Lanuti M, Rusch VW, Kris MG, Sequist LV. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol. 2019 Jan 10; 37(2):97-104. PMID: 30444685.
    Citations:    Fields:    
  5. Cheng MP, Marty FM, Costa DB, Awad MM. Authors' Response. J Thorac Oncol. 2018 11; 13(11):e237. PMID: 30368420.
    Citations:    Fields:    
  6. Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol. 2018 Nov 01; 4(11):1527-1534. PMID: 30073261.
    Citations:    Fields:    
  7. Costa DB. TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer. Ann Oncol. 2018 Oct 01; 29(10):2028-2030. PMID: 30265285.
    Citations:    Fields:    
  8. Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol. 2018 Oct 01; 29(10):2092-2097. PMID: 30351341.
    Citations:    Fields:    
  9. VanderLaan PA, Rangachari D, Costa DB. Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018 09 13; 379(11):1093. PMID: 30211492.
    Citations:    Fields:    Translation:Humans
  10. Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB. EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2018 Dec 15; 24(24):6548-6555. PMID: 30154228.
    Citations:    Fields:    
  11. Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 Dec 01; 24(23):5963-5976. PMID: 30072474.
    Citations:    Fields:    
  12. Sehgal K, Patell R, Rangachari D, Costa DB. Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. Transl Cancer Res. 2018 Aug; 7(Suppl 7):S779-S786. PMID: 30327756.
    Citations:    
  13. Sehgal K, Peters MLB, VanderLaan PA, Rangachari D, Kobayashi SS, Costa DB. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. J Thorac Oncol. 2019 Jan; 14(1):e1-e3. PMID: 29981924.
    Citations:    Fields:    
  14. VanderLaan PA, Chen Y, DiStasio M, Rangachari D, Costa DB, Heher YK. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target. Clin Lung Cancer. 2018 09; 19(5):e589-e590. PMID: 29798809.
    Citations:    Fields:    
  15. Rangachari D, VanderLaan PA, Costa DB. Updated Correlation of 22C3-PD-L1 =50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting. J Thorac Oncol. 2018 05; 13(5):e81-e83. PMID: 29703544.
    Citations:    Fields:    
  16. Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 07; 13(7):1037-1042. PMID: 29631035.
    Citations: 2     Fields:    
  17. Shea M, Rangachari D, Hallowell RW, Hollie NI, Costa DB, VanderLaan PA. Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. Cancer Treat Res Commun. 2018; 15:17-20. PMID: 30207283.
    Citations:    
  18. Torous VF, Rangachari D, Gallant BP, Shea M, Costa DB, VanderLaan PA. PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol. 2018 May-Jun; 7(3):133-141. PMID: 29713584.
    Citations: 3     
  19. VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, McDonald DC, Huberman MS, Kobayashi SS, Costa DB. Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer. 2018 02; 116:90-95. PMID: 29413057.
    Citations: 1     Fields:    
  20. Heidinger BH, Anderson KR, Nemec U, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA. Morphologic characteristics of pulmonary adenocarcinomas manifesting as pure ground-glass nodules on CT. J Thorac Dis. 2017 Dec; 9(12):E1148-E1150. PMID: 29313855.
    Citations:    
  21. Le X, Rangachari D, Costa DB. Moving more potent and less toxic options to the frontline in the management of advanced lung cancer. J Thorac Dis. 2017 Sep; 9(9):2812-2818. PMID: 29221246.
    Citations:    
  22. Carney BJ, Rangachari D, VanderLaan PA, Gowen K, Schrock AB, Ali SM, Costa DB. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma. Lung Cancer. 2017 12; 114:108-110. PMID: 28870636.
    Citations: 2     Fields:    Translation:Humans
  23. Heidinger BH, Nemec U, Anderson KR, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA. "Rounding" the Size of Pulmonary Nodules: Impact of Rounding Methods on Nodule Management, as Defined by the 2017 Fleischner Society Guidelines. Acad Radiol. 2017 11; 24(11):1422-1427. PMID: 28666724.
    Citations:    Fields:    Translation:Humans
  24. Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, Costa DB. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol. 2017 11; 12(11):e175-e177. PMID: 28611010.
    Citations: 2     Fields:    Translation:Humans
  25. Costa DB. Ascending role of next-generation ALK inhibitors. Lancet Oncol. 2017 07; 18(7):837-839. PMID: 28602777.
    Citations: 2     Fields:    Translation:Humans
  26. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209. PMID: 28579481.
    Citations: 7     Fields:    Translation:Humans
  27. Heidinger BH, Anderson KR, Nemec U, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA. Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size. J Thorac Oncol. 2017 08; 12(8):1288-1298. PMID: 28576745.
    Citations: 7     Fields:    Translation:Humans
  28. Peters MLB, Costa DB, Rangachari D. Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies. J Thorac Oncol. 2017 04; 12(4):e35-e36. PMID: 28343545.
    Citations:    Fields:    Translation:Humans
  29. DiStasio M, Chen Y, Rangachari D, Costa DB, Heher YK, VanderLaan PA. Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis. Clin Lung Cancer. 2017 09; 18(5):e349-e356. PMID: 28377205.
    Citations: 2     Fields:    Translation:Humans
  30. Heidinger BH, Anderson KR, Moriarty EM, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA. Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules =30?mm on CT: Radiology-Pathology Correlation. Acad Radiol. 2017 07; 24(7):851-859. PMID: 28256438.
    Citations: 3     Fields:    Translation:Humans
  31. Rangachari D, Costa DB. Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. Transl Cancer Res. 2017 Feb; 6(Suppl 1):S151-S157. PMID: 30613479.
    Citations:    
  32. VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017 04; 106:17-21. PMID: 28285689.
    Citations: 11     Fields:    Translation:Humans
  33. Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 =50% Expression in Lung Adenocarcinoma. J Thorac Oncol. 2017 05; 12(5):878-883. PMID: 28104537.
    Citations: 12     Fields:    Translation:Humans
  34. Costa DB. Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling? Cell Cycle. 2017 01 02; 16(1):19-20. PMID: 27764548.
    Citations: 1     Fields:    Translation:Humans
  35. Redig AJ, Costa DB, Taibi M, Boucher D, Johnson BE, Jänne PA, Jackman DM. Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. JAMA Oncol. 2016 Sep 01; 2(9):1240-2. PMID: 27387964.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  36. Rangachari D, Drake L, Huberman MS, McDonald DC, VanderLaan PA, Folch E, Costa DB. Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice. Cancer Treat Commun. 2016; 9:41-43. PMID: 28111612.
    Citations:    
  37. Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer. 2016 09; 99:17-22. PMID: 27565908.
    Citations: 3     Fields:    Translation:HumansCells
  38. Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, Costa DB. EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. Clin Lung Cancer. 2016 11; 17(6):483-492. PMID: 27381270.
    Citations: 6     Fields:    Translation:Humans
  39. Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clin Cancer Res. 2016 Dec 15; 22(24):6010-6020. PMID: 27281561.
    Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
  40. Costa DB. Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements. Transl Lung Cancer Res. 2016 Jun; 5(3):331-7. PMID: 27413714.
    Citations: 5     
  41. Nemeth Z, Csizmadia E, Vikstrom L, Li M, Bisht K, Feizi A, Otterbein S, Zuckerbraun B, Costa DB, Pandolfi PP, Fillinger J, Döme B, Otterbein LE, Wegiel B. Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth. Oncotarget. 2016 Apr 26; 7(17):23919-32. PMID: 26993595.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  42. Gao X, VanderLaan PA, Bailey AS, Costa DB. Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late Recurrence. Clin Lung Cancer. 2016 09; 17(5):e169-e172. PMID: 27103378.
    Citations:    Fields:    Translation:Humans
  43. Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. J Clin Oncol. 2016 08 20; 34(24):2858-65. PMID: 27022118.
    Citations: 39     Fields:    Translation:HumansCTClinical Trials
  44. Gao X, Le X, Costa DB. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2016; 16(4):383-90. PMID: 26943236.
    Citations: 9     Fields:    Translation:Humans
  45. Costa DB. ALK inhibitors: plateauing systemic and intracranial activity? Lancet Oncol. 2016 04; 17(4):404-406. PMID: 26973321.
    Citations: 3     Fields:    Translation:Humans
  46. Costa DB, Jorge SE, Moran JP, Freed JA, Zerillo JA, Huberman MS, Kobayashi SS. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. J Thorac Oncol. 2016 06; 11(6):918-23. PMID: 26964772.
    Citations: 5     Fields:    Translation:HumansCells
  47. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17; 7:10501. PMID: 26883990.
    Citations: 153     Fields:    Translation:HumansAnimals
  48. Shea M, Huberman MS, Costa DB. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma. J Thorac Oncol. 2016 07; 11(7):e81-2. PMID: 26845194.
    Citations: 6     Fields:    Translation:Humans
  49. Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1670-4. PMID: 26565381.
    Citations: 31     Fields:    Translation:Humans
  50. Costa DB, Kobayashi SS. Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. Transl Lung Cancer Res. 2015 Dec; 4(6):809-15. PMID: 26798593.
    Citations: 12     
  51. Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016 Apr; 10(2):113-29. PMID: 26620497.
    Citations: 21     Fields:    Translation:Humans
  52. Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, Betsuyaku T, Soejima K. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget. 2015 Nov 17; 6(36):38789-803. PMID: 26515464.
    Citations: 13     Fields:    Translation:HumansCells
  53. Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, Huberman MS, Costa DB. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer. 2015 Dec; 90(3):369-74. PMID: 26791794.
    Citations: 16     Fields:    Translation:HumansCells
  54. Folch E, Costa DB, Wright J, VanderLaan PA. Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. Transl Lung Cancer Res. 2015 Aug; 4(4):392-403. PMID: 26380180.
    Citations: 2     
  55. Chen CA, Costa DB, Wu PA. Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycycline. JAAD Case Rep. 2015 Sep; 1(5):289-91. PMID: 27051756.
    Citations:    
  56. Klempner SJ, Ou SH, Costa DB, VanderLaan PA, Sanford EM, Schrock A, Gay L, Ali SM, Miller VA. The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review. Clin Lung Cancer. 2015 Sep; 16(5):334-339.e1. PMID: 25911330.
    Citations: 4     Fields:    Translation:Humans
  57. Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer. 2015 Sep; 16(5):e105-9. PMID: 25922291.
    Citations: 3     Fields:    Translation:Humans
  58. Cai Y, Hirata A, Nakayama S, VanderLaan PA, Levantini E, Yamamoto M, Hirai H, Wong KK, Costa DB, Watanabe H, Kobayashi SS. CCAAT/enhancer binding protein ß is dispensable for development of lung adenocarcinoma. PLoS One. 2015; 10(3):e0120647. PMID: 25767874.
    Citations:    Fields:    Translation:HumansAnimalsCells
  59. Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, Miyoshi N, VanderLaan PA, Costa DB, Jänne PA, Borger DR, Ramaswamy S, Shioda T, Iafrate AJ, Getz G, Rudin CM, Mino-Kenudson M, Engelman JA. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015 Mar 11; 6:6377. PMID: 25758528.
    Citations: 85     Fields:    Translation:HumansCells
  60. Le X, Desai NV, Majid A, Karp RS, Huberman MS, Rangachari D, Kent MS, Gangadharan SP, Folch E, VanderLaan PA, Costa DB. De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung Cancer. 2015 Apr; 88(1):70-3. PMID: 25700797.
    Citations: 5     Fields:    Translation:Humans
  61. Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015 Apr; 88(1):108-11. PMID: 25682925.
    Citations: 50     Fields:    Translation:Humans
  62. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crinò L. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol. 2015 Jun 10; 33(17):1881-8. PMID: 25624436.
    Citations: 126     Fields:    Translation:Humans
  63. Rangachari D, VanderLaan PA, Le X, Folch E, Kent MS, Gangadharan SP, Majid A, Haspel RL, Joseph LJ, Huberman MS, Costa DB. Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treat Commun. 2015; 4:174-181. PMID: 26601054.
    Citations: 11     
  64. Costa DB. Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer. Transl Lung Cancer Res. 2014 Dec; 3(6):373-5. PMID: 25806324.
    Citations:    
  65. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20; 371(21):1963-71. PMID: 25264305.
    Citations: 274     Fields:    Translation:HumansCTClinical Trials
  66. Jorge SE, Kobayashi SS, Costa DB. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res. 2014 Sep 05; 0:0. PMID: 25211582.
    Citations:    
  67. Jorge SE, Kobayashi SS, Costa DB. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res. 2014 Nov; 47(11):929-39. PMID: 25296354.
    Citations: 23     Fields:    Translation:Humans
  68. Nakayama S, Sng N, Carretero J, Welner R, Hayashi Y, Yamamoto M, Tan AJ, Yamaguchi N, Yasuda H, Li D, Soejima K, Soo RA, Costa DB, Wong KK, Kobayashi SS. ß-catenin contributes to lung tumor development induced by EGFR mutations. Cancer Res. 2014 Oct 15; 74(20):5891-902. PMID: 25164010.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  69. Honma HN, Perroud MW, Leme MS, Barbeiro AS, Saad BA, Morcillo AM, Vassallo J, Costa DB, Zambon L. EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients. Target Oncol. 2014 Dec; 9(4):389-94. PMID: 24793378.
    Citations: 2     Fields:    Translation:Humans
  70. de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS, Costa DB. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. J Thorac Oncol. 2014 Feb; 9(2):248-53. PMID: 24419423.
    Citations: 4     Fields:    Translation:HumansCells
  71. Vanderlaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, Majid A, Goldstein MA, Huberman MS, Kocher ON, Costa DB. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer. 2014 Apr; 84(1):39-44. PMID: 24513263.
    Citations: 30     Fields:    Translation:Humans
  72. Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book. 2014; e353-65. PMID: 24857124.
    Citations: 26     Fields:    Translation:Humans
  73. Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013 Dec 18; 5(216):216ra177. PMID: 24353160.
    Citations: 67     Fields:    Translation:HumansCells
  74. Oxnard GR, Nguyen KS, Costa DB. Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking history. J Natl Cancer Inst. 2014 Jan; 106(1):djt361. PMID: 24317178.
    Citations: 2     Fields:    Translation:Humans
  75. Folch E, Yamaguchi N, VanderLaan PA, Kocher ON, Boucher DH, Goldstein MA, Huberman MS, Kent MS, Gangadharan SP, Costa DB, Majid A. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. J Thorac Oncol. 2013 Nov; 8(11):1438-1444. PMID: 24128714.
    Citations: 9     Fields:    Translation:Humans
  76. Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE, Hammerman PS. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol. 2013 Nov; 8(11):1434-7. PMID: 24128713.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  77. Yamaguchi N, Lucena-Araujo AR, Nakayama S, de Figueiredo-Pontes LL, Gonzalez DA, Yasuda H, Kobayashi S, Costa DB. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer. 2014 Jan; 83(1):37-43. PMID: 24199682.
    Citations: 31     Fields:    Translation:HumansCells
  78. Yamaguchi N, Vanderlaan PA, Folch E, Boucher DH, Canepa HM, Kent MS, Gangadharan SP, Majid A, Kocher ON, Goldstein MA, Huberman MS, Costa DB. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Lung Cancer. 2013 Oct; 82(1):31-7. PMID: 23932486.
    Citations: 18     Fields:    Translation:Humans
  79. Costa DB. Identification of somatic genomic alterations in circulating tumors cells: another step forward in non-small-cell lung cancer? J Clin Oncol. 2013 Jun 20; 31(18):2236-9. PMID: 23669228.
    Citations:    
  80. Srivastava N, VanderLaan PA, Kelly CP, Costa DB. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):e23-4. PMID: 23407563.
    Citations: 3     Fields:    Translation:Humans
  81. Klempner SJ, Costa DB, Wu PA, Ariyabuddhiphongs KD. Safety of cupping during bevacizumab therapy. J Altern Complement Med. 2013 Aug; 19(8):729-31. PMID: 23379829.
    Citations: 2     Fields:    Translation:Humans
  82. Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS, Costa DB. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013 Jan; 8(1):45-51. PMID: 23242437.
    Citations: 31     Fields:    Translation:HumansCells
  83. Gaughan EM, Cryer SK, Yeap BY, Jackman DM, Costa DB. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations. Lung Cancer. 2013 Mar; 79(3):193-7. PMID: 23273562.
    Citations: 9     Fields:    Translation:Humans
  84. Ackerman A, Goldstein MA, Kobayashi S, Costa DB. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer. J Thorac Oncol. 2012 Oct; 7(10):e19-20. PMID: 22982663.
    Citations: 4     Fields:    Translation:Humans
  85. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012 Oct; 13(10):1011-9. PMID: 22954507.
    Citations: 345     Fields:    Translation:HumansCTClinical Trials
  86. Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, Awad MM, Engelman JA, Riely GJ, Monica V, Yeap BY, Scagliotti GV. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):59-66. PMID: 22887466.
    Citations: 27     Fields:    Translation:Humans
  87. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 2012 Jul; 7(7):1086-90. PMID: 22617245.
    Citations: 39     Fields:    Translation:HumansCells
  88. Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012 Aug 15; 18(16):4406-14. PMID: 22733536.
    Citations: 48     Fields:    Translation:Humans
  89. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, Wang S, Lee C, Nakada Y, Peña CG, Sun Y, Franchetti Y, Yao C, Saur A, Cameron MD, Nishino M, Hayes DN, Wilkerson MD, Roberts PJ, Lee CB, Bardeesy N, Butaney M, Chirieac LR, Costa DB, Jackman D, Sharpless NE, Castrillon DH, Demetri GD, Jänne PA, Pandolfi PP, Cantley LC, Kung AL, Engelman JA, Wong KK. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012 Mar 18; 483(7391):613-7. PMID: 22425996.
    Citations: 153     Fields:    Translation:HumansAnimalsCells
  90. Costa DB, Kobayashi S. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. J Thorac Oncol. 2012 Mar; 7(3):623-5. PMID: 22334013.
    Citations: 8     Fields:    Translation:Humans
  91. Basseres DS, D'Alò F, Yeap BY, Löwenberg EC, Gonzalez DA, Yasuda H, Dayaram T, Kocher ON, Godleski JJ, Richards WG, Meyerson M, Kobayashi S, Tenen DG, Halmos B, Costa DB. Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer. 2012 Jul; 77(1):31-7. PMID: 22341411.
    Citations: 10     Fields:    Translation:HumansCells
  92. Nguyen KS, Sanford RA, Huberman MS, Goldstein MA, McDonald DM, Farquhar M, Gangadharan SP, Kent MS, Michaud G, Majid A, Berman SM, Aronovitz JA, Nedea EA, Boiselle PM, Cohen DW, Kobayashi S, Costa DB. Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. J Oncol Pract. 2012 Jan; 8(1):57-62. PMID: 22548013.
    Citations: 2     Fields:    
  93. Costa DB. More than just an oncogene translocation and a kinase inhibitor: Kevin's story. J Clin Oncol. 2012 Jan 01; 30(1):110-2. PMID: 22067391.
    Citations:    Fields:    Translation:HumansCells
  94. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011 Oct; 12(11):1004-12. PMID: 21933749.
    Citations: 271     Fields:    Translation:Humans
  95. Klempner SJ, Cohen DW, Costa DB. ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. J Thorac Oncol. 2011 Aug; 6(8):1439-40. PMID: 21847065.
    Citations: 6     Fields:    Translation:Humans
  96. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012 Jan; 13(1):e23-31. PMID: 21764376.
    Citations: 107     Fields:    Translation:HumansAnimalsCells
  97. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011 Aug 20; 29(24):3307-15. PMID: 21768463.
    Citations: 144     Fields:    Translation:HumansCTClinical Trials
  98. Britt GJ, Gaughan EM, Nguyen KS, Warner JL, Goldstein MA, Huberman MS, Costa DB. Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer. J Thorac Dis. 2011 Jun; 3(2):141-3. PMID: 22263078.
    Citations:    
  99. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Iafrate AJ, Shapiro G, Costa DB, Butaney M, Ou SI, Maki RG, Bang Y, Varella-Garcia M, Salgia R, Wilner KD, Kulig K, Selaru P, Tang Y, Kwak EL, Clark JW, Camidge DR. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. J Clin Oncol. 2011 May 20; 29(15_suppl):7507. PMID: 28023300.
    Citations:    
  100. Camidge DR, Bang Y, Kwak EL, Shaw AT, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Wilner KD, Costa DB, Shapiro G, LoRusso P, Stephenson P, Tang Y, Ruffner K, Clark JW. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2011 May 20; 29(15_suppl):2501. PMID: 28022383.
    Citations:    
  101. Pennell NA, Neal JW, Govindan R, Janne PA, Evans TL, Costa DB, Rosovsky RP, Lanuti M, Azzoli CG, Sequist LV. The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR). J Clin Oncol. 2011 May 20; 29(15_suppl):TPS209. PMID: 28023496.
    Citations:    
  102. Nguyen KH, Huberman M, Goldstein M, Kobayashi S, Costa DB. Patterns of care for non-small cell lung cancer at an academic institution affiliated with a National Cancer Institute-designated cancer center: Beth Israel Deaconess Medical Center. J Clin Oncol. 2011 May 20; 29(15_suppl):e18034. PMID: 28020790.
    Citations:    
  103. Gaughan EM, Costa DB. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol. 2011 May; 3(3):113-25. PMID: 21904575.
    Citations: 36     
  104. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, Wilner KD. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011 May 20; 29(15):e443-5. PMID: 21422405.
    Citations: 149     Fields:    Translation:Humans
  105. Ortiz TM, Cohen DW, Kent MS, Jänne PA, Costa DB. KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma. J Thorac Oncol. 2011 Jan; 6(1):220-2. PMID: 21178719.
    Citations:    Fields:    Translation:Humans
  106. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703. PMID: 20979469.
    Citations: 1291     Fields:    Translation:HumansCTClinical Trials
  107. Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010 Dec 01; 16(23):5873-82. PMID: 21030498.
    Citations: 66     Fields:    Translation:Humans
  108. Cheng H, Xu X, Costa DB, Powell CA, Halmos B. Molecular testing in lung cancer: the time is now. Curr Oncol Rep. 2010 Sep; 12(5):335-48. PMID: 20623207.
    Citations: 10     Fields:    Translation:Humans
  109. Costa DB, Kobayashi S, Yeo WL, Hamada A. Serum concentrations of Erlotinib at a dose of 25 mg daily. J Thorac Oncol. 2010 Aug; 5(8):1311-2. PMID: 20661096.
    Citations: 3     Fields:    Translation:Humans
  110. Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul; 5(7):1048-53. PMID: 20512075.
    Citations: 28     Fields:    Translation:HumansCells
  111. Will B, Siddiqi T, Jordà MA, Shimamura T, Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG, Kobayashi S. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 2010 Apr 08; 115(14):2901-9. PMID: 20160166.
    Citations: 24     Fields:    Translation:HumansCells
  112. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10; 27(26):4247-53. PMID: 19667264.
    Citations: 507     Fields:    Translation:Humans
  113. Honma HN, De Capitani EM, Barbeiro Ade S, Costa DB, Morcillo A, Zambon L. Polymorphism of the CYP1A1*2A gene and susceptibility to lung cancer in a Brazilian population. J Bras Pneumol. 2009 Aug; 35(8):767-72. PMID: 19750329.
    Citations: 2     Fields:    Translation:Humans
  114. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009 Jul; 10(4):281-9. PMID: 19632948.
    Citations: 131     Fields:    Translation:Humans
  115. Costa DB, Kobayashi S. Gefitinib plus docetaxel in non-small-cell lung cancer. Lancet. 2009 Feb 14; 373(9663):541; author reply 542. PMID: 19217979.
    Citations:    Fields:    Translation:Humans
  116. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 Nov 01; 14(21):7060-7. PMID: 18981003.
    Citations: 57     Fields:    Translation:Humans
  117. Germano CM, Castro Md, Rorato R, Costa DB, Antunes-Rodrigues J, Elias CF, Elias LL. Downregulation of melanocortin-4 receptor during refeeding and its modulation by adrenalectomy in rats. Horm Metab Res. 2008 Dec; 40(12):842-7. PMID: 18810709.
    Citations:    Fields:    Translation:Animals
  118. Costa DB, Cho BC, Sequist LV, Riely GJ, Halmos B, Kim J, Huberman MS, Pao W, Tenen DG, Kobayashi S. Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib. J Clin Oncol. 2008 May 20; 26(15_suppl):8105. PMID: 27948816.
    Citations:    
  119. Costa DB, Schumer ST, Tenen DG, Kobayashi S. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol. 2008 Mar 01; 26(7):1182-4; author reply 1184-6. PMID: 18309959.
    Citations: 38     Fields:    Translation:Humans
  120. Honma HN, De Capitani EM, Perroud MW, Barbeiro AS, Toro IF, Costa DB, Lima CS, Zambon L. Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population. Lung Cancer. 2008 Aug; 61(2):152-62. PMID: 18280004.
    Citations: 19     Fields:    Translation:Humans
  121. Costa DB, Kobayashi S. Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations. J Clin Oncol. 2008 Feb 01; 26(4):686. PMID: 18235134.
    Citations: 1     Fields:    Translation:Humans
  122. Costa DB, Kobayashi S, Schumer ST. Erlotinib-associated alopecia in a lung cancer patient. J Thorac Oncol. 2007 Dec; 2(12):1136-8. PMID: 18090591.
    Citations: 2     Fields:    Translation:Humans
  123. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007 Oct; 4(10):1669-79; discussion 1680. PMID: 17973572.
    Citations: 190     Fields:    Translation:HumansCells
  124. Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B, Rosenbauer F, Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O'Brien KB, Verhaak RG, Delwel R, Haase D, Trümper L, Krauter J, Kohwi-Shigematsu T, Griesinger F, Tenen DG. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest. 2007 Sep; 117(9):2611-20. PMID: 17694175.
    Citations: 49     Fields:    Translation:HumansAnimalsCells
  125. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007 Oct; 58(1):95-103. PMID: 17610986.
    Citations: 53     Fields:    Translation:Humans
  126. Costa DB. To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress. Lung Cancer. 2007 Aug; 57(2):251-2. PMID: 17566601.
    Citations: 1     Fields:    Translation:Humans
  127. Costa DB, Li S, Kocher O, Feins RH, Keller SM, Schiller JH, Johnson DH, Tenen DG, Halmos B. Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. Lung Cancer. 2007 Apr; 56(1):97-103. PMID: 17239984.
    Citations: 9     Fields:    Translation:HumansCells
  128. Costa DB, Kobayashi S. Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different? Br J Cancer. 2007 Jan 29; 96(2):399; author reply 400. PMID: 17224926.
    Citations: 3     Fields:    Translation:Humans
  129. Steidl U, Rosenbauer F, Verhaak RG, Gu X, Ebralidze A, Otu HH, Klippel S, Steidl C, Bruns I, Costa DB, Wagner K, Aivado M, Kobbe G, Valk PJ, Passegué E, Libermann TA, Delwel R, Tenen DG. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet. 2006 Nov; 38(11):1269-77. PMID: 17041602.
    Citations: 65     Fields:    Translation:HumansAnimalsCells
  130. Costa DB, Huberman MS. Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib. Diabetes Care. 2006 Jul; 29(7):1711. PMID: 16801611.
    Citations: 10     Fields:    Translation:Humans
  131. Costa DB, Miksad RA, Buff MS, Wang Y, Dezube BJ. Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient. J Natl Med Assoc. 2006 Jul; 98(7):1183-7. PMID: 16895293.
    Citations: 5     Fields:    Translation:Humans
  132. Costa DB, Stephenson P, Kocher O, Tenen DG, Feins RH, Keller SM, Schiller JH, Johnson DH, Halmos B. C/EBPa expression by immunohistochemistry lacks prognostic or predictive significance in primary resected non-small cell lung cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7202. PMID: 27954067.
    Citations:    
  133. Costa DB, Dayaram T, D'Alo F, Wouters BJ, Tenen DG, Meyerson M, Tsao MS, Halmos B. C/EBP alpha mutations in lung cancer. Lung Cancer. 2006 Aug; 53(2):253-4. PMID: 16765476.
    Citations: 13     Fields:    Translation:HumansCells
  134. Costa DB, Schumer ST. Three-year survival in metastatic non-small cell lung cancer treated with gefitinib. Lung Cancer. 2006 Jul; 53(1):123-4. PMID: 16723171.
    Citations: 1     Fields:    Translation:Humans
  135. Costa DB, Fisher CA, Miller KB, Pihan GA, Steensma DP, Gibbons RJ, Higgs DR. 5-Azacytidine treatment of the patient with ATMDS. Eur J Haematol. 2006; 76:453.
  136. Costa DB. Recurrent infections in multiple myeloma. Mayo Clin Proc. 2006 Apr; 81(4):567-8; author reply 568. PMID: 16610581.
    Citations:    Fields:    Translation:Humans
  137. Costa DB, Fisher CA, Miller KB, Pihan GA, Steensma DP, Gibbons RJ, Higgs DR. A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome. Eur J Haematol. 2006 May; 76(5):432-5, 453. PMID: 16480427.
    Citations: 2     Fields:    Translation:Humans
  138. Costa DB, Stuart KE, Inzucchi SE. Hyperglycemia and biliary tract adenocarcinoma. J Gastroenterol Hepatol. 2006 Feb; 21(2):484-5. PMID: 16509886.
    Citations:    Fields:    Translation:Humans
  139. Costa DB, Parker JA, Schumer ST. Modern treatment of lung cancer: case 3. Non-metastatic bilateral F-18 fluorodeoxyglucose avid adrenal glands in non-small-cell lung cancer. J Clin Oncol. 2005 Oct 20; 23(30):7740-2. PMID: 16234534.
    Citations:    Fields:    Translation:Humans
  140. Costa DB, Lozovatsky L, Gallagher PG, Forget BG. A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindred. Blood. 2005 Dec 15; 106(13):4367-9. PMID: 16150946.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  141. Bonon SH, Menoni SM, Rossi CL, De Souza CA, Vigorito AC, Costa DB, Costa SC. Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients. J Infect. 2005 Feb; 50(2):130-7. PMID: 15667914.
    Citations: 8     Fields:    Translation:HumansCellsPHPublic Health
  142. Costa DB, Shin B, Cooper DL. Pneumococcemia as the presenting feature of multiple myeloma. Am J Hematol. 2004 Nov; 77(3):277-81. PMID: 15495248.
    Citations: 3     Fields:    Translation:HumansCells
  143. Costa DB, Chen AA, Marginean EC, Inzucchi SE. Diabetes mellitus as the presenting feature of extrahepatic cholangiocarcinoma in situ: case report and review of literature. Endocr Pract. 2004 Sep-Oct; 10(5):417-23. PMID: 15760789.
    Citations:    Fields:    Translation:Humans
  144. Costa DB, Aguiar JF, Varanda WA. Diversity of ion channels in HCl secreting cells of Rana castebeiana. Annals of the VI Symposium of Scientific Initiation of the University of Sao Paulo (USP). 1998; 1:(abstract 9.16):142. .
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Costa's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (373)
Explore
_
Co-Authors (105)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.